Clinical Study
Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series
Table 2
Mean (SD) and
values of paired
-tests of scores at baseline and at latest followup.
| | | Before Duodopa
()
Mean (SD) | 1 month
()
Mean (SD) | 3 months
()
Mean (SD) | Latest
(1)
Mean (SD) |
Before versus latest
value |
| | Mobility | 76.4 (19.9) | 62.8 (24.0) | 56.8 (29.5) | 56.3 (13.0) |
0.04 | | ADL | 62.1 (17.1) | 55.2 (24.2) | 50.0 (27.8) | 52.6 (24.9) |
0.23 | | Emotional well-being | 45.8 (13.1) | 40.7 (7.8) | 38.3 (9.4) | 38.6 (9.1) |
0.13 | | Sense of stigma | 33.5 (16.8) | 24.9 (15.8) | 16.3 (15.4) | 19.3 (17.7) |
0.03 | | Social support | 22.0 (20.5) | 14.3 (13.5) | 17.5 (9.2) | 18.8 (14.3) |
0.32 | | Cognition | 52.8 (20.6) | 37.1 (17.8) | 32.5 (12.7) | 32.4 (10.4) |
0.02 | | Communication | 53.0 (17.6) | 40.6 (22.9) | 35 (24.2) | 40.9 (25.1) |
0.19 | | Bodily discomfort | 52.3 (23.6) | 53.8 (22.8) | 40 (25.4) | 49.2 (28.0) |
0.59 | | Summary index | 49.7 (10.4) | 41.3 (11.1) | 35.8 (13.3) | 38.7 (11.2) |
0.02 |
|
|
